Caladrius Biosciences to Participate at the Upcoming May Conferences
May 07 2019 - 8:30AM
Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the
“Company”), a late-stage therapeutics development biopharmaceutical
company committed to the development of innovative products that
have the potential to restore the health of people with chronic
illnesses and with a focus on select cardiovascular indications,
announced today that management will participate in the following
conferences in May:
16th International Symposium on Cardiovascular
Regeneration and Repair
Title: |
The Microcirculation: Center of the
Cardiovascular Repair Universe |
Date & Time: |
Thursday, May 9, 2019 at 4:30 p.m. (GMT+2) |
Presenter: |
Douglas Losordo, M.D., FACC, FAHA, Executive Vice
President, Global Head of Research and Development, Chief Medical
Officer |
Venue: |
Hospital General Universitario Gregorio Marañón,
Aula Magna del Pabellón Docente in Madrid, Spain |
2019 World Advanced Therapies & Regenerative
Medicine Congress
Oral Presentation:
Title: |
Single Administration of CD34 cell Reverses
Cardiovascular disease: Evidence from >700 patients in
randomized clinical trials |
Date & Time: |
Thursday, May 16, 2019 at 4:05 p.m.
(GMT+1) |
Presenter: |
Douglas Losordo, M.D., FACC, FAHA, Executive Vice
President, Global Head of Research and Development, Chief Medical
Officer |
Dr. Losordo will also participate in a panel discussion,
entitled, “Clinical Development of Cell Therapies (CAR-T, DCs,
Tregs etc.),” on Thursday, May 16, 2019 at 5:45 p.m. (GMT+1).
Corporate Presentation:
Topic: |
Company Overview |
Date & Time: |
Thursday, May 16, 2019 at 4:15 p.m.
(GMT+1) |
Presenter: |
David Mazzo, Ph.D., President and Chief Executive
Officer |
The 2019 World Advanced Therapies & Regenerative Medicine
Congress will be held at the Business Design Centre in London,
England.
About Caladrius Biosciences
Caladrius is a late-stage therapeutics development
biopharmaceutical company committed to the development of
innovative products that have the potential to restore the health
of people with chronic illnesses. Our leadership team collectively
has decades of biopharmaceutical development experience and
world-recognized scientific achievement in the fields of
cardiovascular and autoimmune disease, among other areas. The
Company’s goal is to build a broad portfolio of novel and versatile
products that address important unmet medical needs. Our current
product candidates include three developmental treatments for
cardiovascular diseases based on our CD34 cell therapy platform:
CLBS12, recipient of SAKIGAKE designation, in Phase 2 testing in
Japan and eligible for early conditional approval for the treatment
of critical limb ischemia; CLBS14-CMD, in Phase 2 testing for the
treatment of coronary microvascular dysfunction; and CLBS14-NORDA
(formerly CLBS14-RfA) in late-stage development for no option
refractory disabling angina for which it has received RMAT
designation. For more information on the company, please visit
www.caladrius.com.
Contact:
Investors: Caladrius Biosciences, Inc. John Menditto Vice
President, Investor Relations and Corporate Communications
Phone: +1-908-842-0084
Email: jmenditto@caladrius.com
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From Apr 2024 to May 2024
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From May 2023 to May 2024